Stockreport
Genetic Modification Therapies Set to Surge, Market Valued at $32.1 Billion by 2030 [Yahoo! Finance]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Emerging applications extend to oncology, cardiovascular, and neurological diseases, supported by a robust clinical pipeline and growing biopharmaceutical industry interest. Genetic Modification Therapies Market Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing" has been added to ResearchAndMarkets.com's offering. The global market for genetic modification therapies is projected to expand from $14.8 billion in 2025 to $32.1 billion by 2030, boasting a compound annual growth rate (CAGR) of 16.8% within this period. Genetic modification therapies represent cutting-edge biologic interventions developed by altering genetic material. The promising platforms in this sector, including gene therapy and RNA therapy, are poised to transform treatment for conditions that currently have limited therapeutic options. These specialized therapies, often design
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Royal Bank Of Canada from $105.00 to $100.00. They now have a "sector perform" rating on the stock.[MarketBeat]
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Hopping Mad Over Drug Company Product Hopping [Forbes][Forbes]
- Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at UBS Group AG.[MarketBeat]
- Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Morgan Stanley from $151.00 to $150.00. They now have an "overweight" rating on the stock.[MarketBeat]
- More
GILD
SEC Filings
SEC Filings
- 1/15/26 - Form 144
- 1/15/26 - Form 144
- 1/5/26 - Form 4
- GILD's page on the SEC website
- More